Table 4.
Representativeness DQI 5: Number of Previous DMTs in CLARION
| MS Registry/Data Source | DQI 5; Number of Previous DMTsa (% of Population) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cladribine Cohort (N=2958) | Fingolimod Cohort (N=2111) | Total (N=5069) | ||||||||||
| 0 | 1 | 2 | ≥3 | 0 | 1 | 2 | ≥3 | 0 | 1 | 2 | ≥3 | |
| Danish MS Registry | 18.0 | 27.8 | 24.3 | 29.8 | 16.4 | 36.6 | 25.2 | 21.8 | 17.0 | 33.6 | 24.9 | 24.5 |
| Finnish MS Registry | 35.8 | 31.0 | 18.8 | 14.4 | 18.6 | 38.7 | 24.2 | 18.6 | 27.9 | 34.5 | 21.3 | 16.3 |
| MSBase (multiple countries) | 34.8 | 38.1 | 17.7 | 9.4 | 18.9 | 65.0 | 13.4 | 2.6 | 26.4 | 52.4 | 15.4 | 5.8 |
| MSDS3D (Germany) | 25.3 | 37.1 | 19.3 | 18.3 | 19.0 | 43.4 | 20.8 | 16.7 | 23.6 | 38.8 | 19.7 | 17.9 |
| Norwegian MS Registry and Biobank | 49.3 | 28.3 | 13.6 | 8.8 | 26.7 | 36.2 | 20.0 | 17.1 | 44.2 | 30.1 | 15.0 | 10.7 |
| Swedish MS Registry | 41.0 | 20.7 | 16.5 | 21.8 | 24.7 | 33.8 | 20.8 | 20.8 | 37.3 | 23.7 | 17.5 | 21.6 |
| Swiss MS Cohort | 36.5 | 25.0 | 11.5 | 26.9 | 56.4 | 25.6 | 12.8 | 5.1 | 45.1 | 25.3 | 12.1 | 17.6 |
| US Department of Defense | 34.9 | 37.3 | 17.8 | 10.1 | 51.0 | 23.8 | 15.6 | 9.5 | 42.4 | 31.0 | 16.8 | 9.8 |
Notes: Cut-off date for most recent data quality indicators: November 1, 2022. aPer protocol, patients were excluded from this study if they had received fingolimod prior to initiating cladribine tablets or received cladribine tablets prior to initiating fingolimod.
Abbreviations: DMT, disease-modifying therapy; DQI, data quality indicator; MS, multiple sclerosis; MSBase, MS Database; MSDS3D, MS Management System 3D.